Ht-Logo-gigapixel-icon
Tuesday, November 5, 2024
Canada’s Politics and Government News Source Since 1989
Tuesday, November 5, 2024 | Latest Paper

ISG Senator Rosemary Moodie

Ontario Senator Rosemary Moodie is a member of the Independent Senators Group.

Canada’s children face barriers to accessing safe and effective medications

Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019
Both the European Medicines Agency and the United States Food and Drug Administration are empowered to demand paediatric studies when a drug is likely to be prescribed for children, and they receive funding to provide incentives for such work. It is bewildering that Health Canada policies seldom require drug manufacturers to submit paediatric data, even when the data has been made available to other jurisdictions or when use among children and youth is foreseeable. Photograph courtesy of Pixabay
Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019
Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019
Both the European Medicines Agency and the United States Food and Drug Administration are empowered to demand paediatric studies when a drug is likely to be prescribed for children, and they receive funding to provide incentives for such work. It is bewildering that Health Canada policies seldom require drug manufacturers to submit paediatric data, even when the data has been made available to other jurisdictions or when use among children and youth is foreseeable. Photograph courtesy of Pixabay
Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019
Both the European Medicines Agency and the United States Food and Drug Administration are empowered to demand paediatric studies when a drug is likely to be prescribed for children, and they receive funding to provide incentives for such work. It is bewildering that Health Canada policies seldom require drug manufacturers to submit paediatric data, even when the data has been made available to other jurisdictions or when use among children and youth is foreseeable. Photograph courtesy of Pixabay
Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019
Opinion | BY ISG SENATOR ROSEMARY MOODIE | September 16, 2019
Both the European Medicines Agency and the United States Food and Drug Administration are empowered to demand paediatric studies when a drug is likely to be prescribed for children, and they receive funding to provide incentives for such work. It is bewildering that Health Canada policies seldom require drug manufacturers to submit paediatric data, even when the data has been made available to other jurisdictions or when use among children and youth is foreseeable. Photograph courtesy of Pixabay